System and method for delivering ultrasonic bladder therapeutic agent
By introducing ultrasonic cavitation technology and balloon structure design into the urinary catheter, and using piezoelectric ceramic elements to generate low-frequency ultrasonic difference signals, the problems of short drug retention time and low absorption efficiency in the bladder are solved, thus improving the treatment effect of bladder cancer.
Patent Information
- Application Number
- CN202410949692.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-08
AI Technical Summary
The short residence time and low absorption efficiency of drugs in the bladder lead to poor treatment outcomes for bladder cancer.
The catheter, designed with ultrasonic cavitation technology and a balloon structure, utilizes piezoelectric ceramic elements to generate low-frequency ultrasonic differential signals, enhancing drug permeability and residence time in the bladder.
It improved the drug delivery rate and efficacy in the bladder, thus enhancing the treatment effect of bladder cancer.
Smart Images

Figure CN118903669A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a system and method for delivering a therapeutic agent, belonging to the technical field of intravesical treatment. Background Art
[0002] Bladder cancer (BC) is the most common histological type of urothelial carcinoma (UC). According to the depth of tumor invasion, about 70% are diagnosed as non-muscle invasive bladder cancer (NMIBC). The incidence of bladder cancer is on the rise, with an estimated annual incidence of 1 to 2 cases per 100,000 people. In addition, the average age of patients diagnosed has increased from 71.5 to 73.4 years, reflecting the trend of BC in elderly patients. Although significant progress has been made in the treatment of BC, according to the American Urological Association (AUA) guidelines, it is strongly recommended that BC patients who meet the inclusion criteria should receive intravesical instillation after surgery to reduce the risk of IVR level a evidence. At present, research on intravesical instillation of BC mainly focuses on postoperative intravesical instillation. If bladder tumors are already present at the time of diagnosis of BC or bladder tumors recur after nephroureterectomy (RNU). Despite the relative success of intravesical instillation, the treatment needs of NMIBC remain unmet. The inherent characteristics of the bladder are the biggest obstacle to the development of effective intravesical instillation for the treatment of NMIBC. Current research is focusing on methods to improve intravesical therapy.
[0003] The bladder is a hollow muscular pelvic organ whose main functions include the storage and drainage of urine. The bladder is relatively impermeable to prevent waste reabsorption. This is accomplished through the bladder permeability barrier (BPB). The BPB consists of a basal layer of germinal cells of 5–10 μm, a middle layer of 20 μm, and an apical layer of umbrella cells of 100–200 μm. Umbrella cells are named for their hexagonal umbrella shape and can change shape and surface area with the filling and contraction of the bladder. The apical surface of umbrella cells consists of asymmetric unit membranes composed of dense plaques composed of uroplaques covering 70–90% of the luminal surface and surrounded by hinged membranes. Umbrella cells are interconnected by tight junctions. These unique features form a barrier between urine and plasma. In addition, the hydrophilic glycosaminoglycan GAG layer of mucin forms a thin water layer on the top of the umbrella cells, which acts as an anti-adhesion and prevents adhesion of foreign particles. While the relative impermeability of the bladder minimizes systemic absorption of drugs and subsequent side effects, it also presents challenges for intravesical drugs to achieve their desired effects. While the urothelium is not completely impermeable, but rather has a small and limited passive permeability through transcellular and paracellular pathways, studies have shown that mammalian bladder epithelium has very low permeability values. More importantly, any drug injected into the bladder is diluted because the bladder constantly receives urine from the kidneys and is rapidly excreted when the bladder is emptied. This reduces both the concentration of the drug and the time the drug is in contact with the target tissue. Studies have found that drug concentration and duration of action are the most important factors in determining tumor response. Prolonging the exposure time results in a proportional decrease in the drug concentration required to achieve the same effect.
[0004] Intravesical therapy is a method that allows drugs to be delivered directly into the urinary bladder, or "bladder" for short. Standard intravesical therapy involves inserting a catheter through the urethra and into the bladder. The lumen that runs along the length of the catheter constitutes a direct route into and out of the bladder, allowing the bladder to be emptied and irrigated with drug solutions. Therefore, how to improve the residence time and absorption of drugs in the bladder is a key issue.
[0005] Ultrasound cavitation is the main mechanism by which ultrasound is used to increase tissue permeability. A composite waveform with multiple parameters such as different waveforms, frequencies, amplitudes and duty cycles is used, and a modulated alternating pulse current is used to cause the transducer to emit ultrasonic waves to act on the bladder wall, causing the structure of the wall to change. This can effectively remove the skin polarization phenomenon and the time lag effect on drug absorption, and further improve the drug's transdermal rate. The ultrasonic cavitation effect will form bubbles and quickly collapse, thereby generating high energy to open certain gaps in the tissue and enhance the tissue's permeability to therapeutic drugs. However, the ultrasonic cavitation effect is better in the low-frequency ultrasound segment, but it cannot enter the body due to size reasons. A transducer that can emit high-frequency ultrasound can enter the body, but the effect is average. Therefore, the present invention provides a method for using ultrasonic difference frequency to enable a small-sized transducer to emit low-frequency ultrasound in the bladder. Summary of the invention
[0006] The present invention aims to solve the problem that the drug stays in the bladder for a short time and has a low absorption efficiency, and further proposes a system and method for delivering an ultrasonic bladder therapeutic agent.
[0007] The technical solution adopted by the present invention to solve the above problems is: the present invention comprises a front end of a urinary catheter, a pipeline, a first airbag, a second airbag, a third airbag, a tap and a piezoelectric ceramic element;
[0008] The front end of the urinary catheter is installed at the front end of the pipeline, the distributor is installed at the rear end of the pipeline, the first airbag, the second airbag, and the third airbag are sequentially mounted on the front part of the pipeline from top to bottom, the piezoelectric ceramic element is installed at the front part of the pipeline, and the piezoelectric ceramic element is located in the second airbag; the side walls of the pipelines in the first airbag, the second airbag, and the third airbag are provided with through holes, and the three through holes are connected to the front end of the urinary catheter.
[0009] Furthermore, the side wall at the front end of the urinary catheter is provided with three fluid inlet and outlet ports along the circumferential direction, and the three fluid inlet and outlet ports correspond to the three through holes one by one.
[0010] Furthermore, a front end surface of the front end of the urinary catheter is provided with an outwardly convex hemispherical buffer head.
[0011] Further, the splitter includes a splitter box and at least three flow channel extension pipes;
[0012] The front end surface of the flow dividing box is connected to the rear end of the pipeline, and the three flow channel extension pipelines are evenly arranged on the rear end surface of the flow dividing box.
[0013] Further, the piezoelectric ceramic element includes a housing, an upper piezoelectric ceramic, a lower piezoelectric ceramic and a piezoelectric ceramic connector;
[0014] The shell is sleeved on the pipe and is located in the second airbag. The upper piezoelectric ceramic and the lower piezoelectric ceramic are arranged in the shell from top to bottom in sequence. The upper piezoelectric ceramic is connected to the lower piezoelectric ceramic through a piezoelectric ceramic connector.
[0015] Furthermore, the shell is made of hard material.
[0016] Furthermore, the upper piezoelectric ceramic and the lower piezoelectric ceramic are both made of annular PZT8 material.
[0017] Furthermore, the piezoelectric ceramic connector is made of heat-resistant hard material.
[0018] Furthermore, the first airbag and the third airbag are made of soft materials, and the second airbag is made of soft high-frequency sound insulation material.
[0019] Furthermore, the sizes of the first airbag and the third airbag after expansion are 10-30 mm, and the size of the second airbag after expansion is 10-20 mm.
[0020] The beneficial effects of the present invention are:
[0021] 1. The present invention delivers various types of bladder therapeutic agents into the bladder of patients and animals through a urinary catheter, and uses the cavitation effect of ultrasound to act on the drugs, so that the drug administration rate is higher and the drug efficacy is better;
[0022] 2. The present invention utilizes the ultrasonic difference frequency principle to excite two or more high-frequency piezoelectric ceramic elements and control the spacing between two or more ultrasonic waves to generate low-frequency difference frequency signals inside the bladder, thereby utilizing low-frequency ultrasonic waves to perform cavitation. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 It is a schematic diagram of the overall structure of the present invention;
[0024] Figure 2 It is an enlarged schematic diagram of the front end of the urinary catheter;
[0025] Figure 3 It is an enlarged schematic diagram of a piezoelectric ceramic element. DETAILED DESCRIPTION
[0026] Specific implementation method 1: Figure 1 As shown, a system for delivering ultrasonic bladder therapeutic agents includes a front end of a urinary catheter 1, a pipe 2, a first balloon 3, a second balloon 4, a third balloon 5, a tap 6 and a piezoelectric ceramic element 7;
[0027] The front end 1 of the urinary catheter is installed at the front end of the pipe 2, the distributor 6 is installed at the rear end of the pipe 2, the first airbag 3, the second airbag 4, and the third airbag 5 are sequentially mounted on the front part of the pipe 2 from top to bottom, the piezoelectric ceramic element 7 is installed at the front part of the pipe 2, and the piezoelectric ceramic element 7 is located in the second airbag 4; the side wall of the pipe 2 in the first airbag 3, the second airbag 4 and the third airbag 5 is provided with through holes 201, and the three through holes 201 are connected to the front end 1 of the urinary catheter.
[0028] Wherein, the diameter of the pipe 2 is 4 to 11 mm and contains multiple channels;
[0029] Among them, the main function of the third airbag 5 is to form a large obstruction so that the front section of the tube 2 can stay inside the bladder; the function of the first airbag 3 is to open the upper wall of the bladder so that there is a certain gap inside the bladder, so that the bladder can accommodate therapeutic agents, and have a certain area to allow the two high-frequency ultrasounds to interact with each other to produce low-frequency signals, and finally produce a cavitation effect to accelerate the pharmacological effect; the first airbag 3 and the third airbag 5 can prevent the transducer device from being effectively fixed, thereby providing safety protection, and the second airbag 4 can isolate high-frequency ultrasound to avoid unnecessary stimulation; 3, different waveguide liquids can be filled to obtain different effects, and can also act as a matching layer to improve transmission efficiency.
[0030] The inner diameters of the three through holes 201 are 3-10 mm, corresponding to the first airbag 3, the second airbag 4, and the third airbag 5, respectively, so as to control the size of the airbag expansion.
[0031] Specific implementation method 2: Figure 2 As shown, based on the first embodiment, the side wall of the front end of the urinary catheter 1 is provided with three fluid inlet and outlet ports 101 along the circumferential direction, and the three fluid inlet and outlet ports 101 correspond to the three through holes 201 one by one.
[0032] Among them, the size of the front end 1 of the urinary catheter is set to be slightly wider or narrower than the front end buffer head, with a height of 4-20mm. The side wall of the front end 1 of the urinary catheter is also provided with a fluid interaction port. The opening of the fluid interaction port is circular or rectangular, and the size is slightly narrower than the port. It is directly connected to the tap 6 through the internal channel of the pipeline, and one or more pipelines in the tap 6 are used to interact with the outside.
[0033] Therein, an adhesive portion is provided between the front end 1 of the urinary catheter and the first air bag 3, the purpose of which is to fix the front end 1 of the urinary catheter on the pipe 2 and provide a connection buffer for the lower air bag.
[0034] Specific implementation method three: Figure 2 As shown, based on the second specific embodiment, the front end surface of the front end 1 of the urinary catheter is provided with a convex hemispherical buffer head 102.
[0035] The buffer head 102 is made of soft material and has a diameter of 4 to 11 mm. The purpose is to allow the catheter to enter the bladder better without irritating or harming the patient or animal.
[0036] Specific implementation method four: Figure 1 As shown, based on the specific embodiment 1, the splitter 6 includes a flow splitter box 601 and at least three flow channel extension pipes 602;
[0037] The front end surface of the diverter box 601 is connected to the rear end of the pipe 2 , and three flow channel extension pipes 602 are evenly distributed on the rear end surface of the diverter box 601 .
[0038] The function of the splitter 6 is to divide the pipe 2 into multiple channels, and use each channel to achieve different functions, including: urination, drug administration, delivery of ultrasonic waveguide, and power supply of piezoelectric element;
[0039] The size of the diversion box 601 depends on the specific diversion situation, and is initially set to be 20-50mm wide, 20-50mm high, and 20-50mm wide; the number of flow channel extension pipes 602 is at least three, and the diameter of each flow channel is not necessarily the same, and the diameter is 10-40mm.
[0040] Specific implementation method five: Figure 3 As shown, based on the first specific embodiment, the piezoelectric ceramic element 7 includes a housing 701, an upper piezoelectric ceramic 702, a lower piezoelectric ceramic 703 and a piezoelectric ceramic connector 704;
[0041] The shell 701 is sleeved on the pipe 2 and is located in the second airbag 4 . The upper piezoelectric ceramic 702 and the lower piezoelectric ceramic 703 are sequentially arranged in the shell 701 from top to bottom. The upper piezoelectric ceramic 702 is connected to the lower piezoelectric ceramic 703 through a piezoelectric ceramic connector 704 .
[0042] Specific implementation method six: Figure 3 As shown, based on the fifth embodiment, the housing 701 is made of hard material.
[0043] The size of the housing 701 is 4-11 mm, the purpose of which is to support the piezoelectric element so that it can work at the resonant frequency as much as possible and to protect the bladder tissue from contacting the piezoelectric element.
[0044] Specific implementation method seven: Figure 3 As shown, based on the fifth specific implementation, the upper piezoelectric ceramic 702 and the lower piezoelectric ceramic 703 are both made of annular PZT8 material.
[0045] Among them, the outer diameter of the upper piezoelectric ceramic 702 and the lower piezoelectric ceramic 703 is 3.9-10.9mm, and the inner diameter is 4.1-10.8mm. The inner diameter and outer diameter of the upper piezoelectric ceramic 702 and the lower piezoelectric ceramic 703 can be different, and can also operate at different resonant frequencies with a frequency difference of 20-100kHz. The frequency of the upper piezoelectric ceramic 702 can be higher or the frequency of the lower piezoelectric ceramic 703 can be higher.
[0046] Specific implementation method eight: Figure 3 As shown, based on the fifth specific implementation, the piezoelectric ceramic connector 704 is made of a heat-resistant hard material.
[0047] The diameter of the piezoelectric ceramic connector 704 is 4-11 mm, and its purpose is to support the upper piezoelectric ceramic 702 and the lower piezoelectric ceramic 703. It has a fluid channel that leads to the inside of the shell 701. The inside of the channel is connected to the inside of 701 and the outside is connected to the tap 6.
[0048] Specific implementation method nine: Figure 1 As shown, based on the specific implementation mode 1, the first airbag 3 and the third airbag 5 are made of soft materials, and the second airbag 4 is made of soft high-frequency sound insulation material.
[0049] Specific implementation method ten: Figure 1 As shown, based on the first specific embodiment, the size of the first airbag 3 and the third airbag 5 after expansion is 10-30 mm, and the size of the second airbag 4 after expansion is 10-20 mm.
[0050] How it works
[0051] First, the buffer head 102 enters the urethral opening, and at this time, a certain amount of liquid is introduced to make the pipe 2 have a certain rigidity, which is enough to insert the front part into the bladder. When the third airbag 5 part enters the bladder, a certain amount of gas is introduced into the third airbag 5 part to make it collide, so as to guide the urine out;
[0052] Then, gas is introduced into the first airbag 3 to expand it so as to obtain a structure with a certain degree of support that is expanded both above and below, and the bladder can be expanded into a cylindrical shape with a diameter of 10-30 mm. Then, the therapeutic agent is input through the fluid introduction and outlet port 101, and most of it stays in the middle part of the two airbags, and the therapeutic agent can contact all the bladder walls;
[0053] The second airbag 4 is introduced into the waveguide liquid, and then different signal excitations are given to the upper piezoelectric ceramic 702 and the lower piezoelectric ceramic 703, so that a low-frequency ultrasonic signal is obtained in the outer area of the second airbag 4, causing a cavitation effect and improving the efficiency of drug treatment.
[0054] The method of using the present invention to treat bladder is:
[0055] Step 1, inserting the distal inflatable portion of the catheter into the bladder through the urethra; draining and flushing the bladder with saline before supplying the gaseous liquid to the bladder;
[0056] Step 2, filling the expansion part with fluid to expand it, and providing a therapeutic fluid to the bladder through at least one therapeutic fluid port in the urinary catheter; the therapeutic fluid may be a gaseous therapeutic fluid;
[0057] Step 3: advance the catheter into the bladder, insert the proximal expandable portion of the catheter into the bladder, expand the proximal expandable portion and fill the space between the distal expandable portion and the proximal expandable portion with a treatment fluid, and use ultrasonic energy to form a cavitation effect in the treatment fluid.
[0058] The above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not used to limit the present invention. Any technician familiar with this profession can make some changes or modify the technical contents disclosed above into equivalent embodiments without departing from the scope of the technical solution of the present invention. However, any simple modification, equivalent replacement and improvement made to the above embodiments without departing from the content of the technical solution of the present invention, based on the technical essence of the present invention, within the spirit and principles of the present invention, still fall within the protection scope of the technical solution of the present invention.
Claims
1. A system for delivering an ultrasonic bladder therapeutic agent, characterized in that: It comprises a front end of a urinary catheter (1), a pipeline (2), a first air bag (3), a second air bag (4), a third air bag (5), a tap (6) and a piezoelectric ceramic element (7); The front end (1) of the urinary catheter is installed at the front end of the pipe (2), the distributor (6) is installed at the rear end of the pipe (2), the first airbag (3), the second airbag (4), and the third airbag (5) are sequentially mounted on the front part of the pipe (2) from top to bottom, the piezoelectric ceramic element (7) is installed at the front part of the pipe (2), and the piezoelectric ceramic element (7) is located in the second airbag (4); the side wall of the pipe (2) in the first airbag (3), the second airbag (4), and the third airbag (5) is provided with through holes (201), and the three through holes (201) are connected to the front end (1) of the urinary catheter.
2. A system for delivering ultrasonic bladder therapeutic agents according to claim 1, characterized in that: The side wall of the front end of the urinary catheter (1) is provided with three fluid inlet and outlet ports (101) along the circumferential direction, and the three fluid inlet and outlet ports (101) correspond to the three through holes (201) one by one.
3. A system for delivering ultrasonic bladder therapeutic agents according to claim 2, characterized in that: The front end surface of the front end of the urinary catheter (1) is provided with an outwardly convex hemispherical buffer head (102).
4. A system for delivering ultrasonic bladder therapeutic agents according to claim 1, characterized in that: The splitter (6) comprises a flow splitter box (601) and at least three flow channel extension pipes (602); The front end surface of the flow diversion box (601) is connected to the rear end of the pipeline (2), and the three flow channel extension pipelines (602) are evenly distributed on the rear end surface of the flow diversion box (601).
5. A system for delivering ultrasonic bladder therapeutic agents according to claim 1, characterized in that: The piezoelectric ceramic element (7) comprises a housing (701), an upper piezoelectric ceramic (702), a lower piezoelectric ceramic (703) and a piezoelectric ceramic connector (704); The housing (701) is sleeved on the pipe (2), and the housing (701) is located in the second airbag (4). The upper piezoelectric ceramic (702) and the lower piezoelectric ceramic (703) are arranged in the housing (701) from top to bottom, and the upper piezoelectric ceramic (702) is connected to the lower piezoelectric ceramic (703) via a piezoelectric ceramic connector (704).
6. A system for delivering an ultrasonic bladder therapeutic agent according to claim 5, characterized in that: The housing (701) is made of hard material.
7. A system for delivering ultrasonic bladder therapeutic agents according to claim 5, characterized in that: The upper piezoelectric ceramic (702) and the lower piezoelectric ceramic (703) are both made of annular PZT8 material.
8. A system for delivering ultrasonic bladder therapeutic agents according to claim 5, characterized in that: The piezoelectric ceramic connector (704) is made of heat-resistant hard material.
9. A system for delivering ultrasonic bladder therapeutic agents according to claim 1, characterized in that: The first airbag (3) and the third airbag (5) are made of soft materials, and the second airbag (4) is made of soft high-frequency sound insulation material.
10. A system for delivering ultrasonic bladder therapeutic agents according to claim 9, characterized in that: The sizes of the first airbag (3) and the third airbag (5) after expansion are 10 to 30 mm, and the size of the second airbag (4) after expansion is 10 to 20 mm.
Citation Information
Cited By
Bladder irrigation teaching and training device
CN122245167A
